Viral Shedding in Mice following Intravenous Adenovirus Injection: Impact on Biosafety Classification

Author:

LaRocca Christopher J.12ORCID,Jacobsen Kari L.1ORCID,Inoko Kazuho1ORCID,Zakharkin Stanislav O.3ORCID,Yamamoto Masato124,Davydova Julia124

Affiliation:

1. Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA

2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA

3. WebMD, New York, NY 10014, USA

4. Institute of Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA

Abstract

There have been numerous advances in gene therapy and oncolytic virotherapy in recent years, especially with respect to cutting-edge animal models to test these novel therapeutics. With all of these advances, it is important to understand the biosafety risks of testing these vectors in animals. We performed adenovirus-based viral shedding studies in murine models to ascertain when it is appropriate to downgrade the animals from Biosafety Level (BSL) 2 to BSL 1 for experimental handling and transport. We utilized intravenous injections of a replication-competent adenovirus and analyzed viral shedding via the collection of buccal and dermal swabs from each animal, in addition to obtaining urine and stool samples. The adenovirus hexon copy number was determined by qPCR, and plaque formation was analyzed to assess the biologic activity of viral particles. Our results demonstrate that after 72 h following viral inoculation, there is no significant quantity of biologically active virus shedding from the animals. This observation suggests that on day 4 following adenovirus injection, mice can be safely downgraded to BSL 1 for the remainder of the experiment with no concern for hazardous exposure to laboratory personnel.

Funder

NIH NCI

National Institutes of Health

Randy Shaver Community Cancer Fund Research Grant

University of Minnesota Masonic Cancer Center

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference31 articles.

1. Oncolytic viruses and checkpoint inhibitors: Combination therapy in clinical trials;LaRocca;Clin. Transl. Med.,2018

2. Delivery and Biosafety of Oncolytic Virotherapy;Li;Front. Oncol.,2020

3. Advances in oncolytic virotherapy;Russell;Commun. Med.,2022

4. Assessment of hazard risk associated with the intravenous use of viral vectors in rodents;Reuter;Comp. Med.,2012

5. Cancer selective adenoviruses;Alemany;Mol. Asp. Med.,2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3